RA Capital funds boost Hemab Therapeutics (COAG) stake with open-market buys
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Hemab Therapeutics Holdings, Inc. reported multiple open-market purchases of its Common Stock by entities associated with RA Capital. Over May 7–11, RA Capital–managed funds bought a total of 51,258 shares at weighted average prices generally between about $23.78 and $25.00 per share, across several transaction ranges noted in the footnotes. Following these purchases, RA Capital–related entities reported indirect ownership of 6,365,783 shares of Hemab common stock. Shares are held directly by RA Capital Healthcare Fund LP, RA Capital Nexus II Fund LP, and RA Capital Nexus IV Fund LP, while RA Capital Management, L.P., its general partner, and principals Peter Kolchinsky and Rajeev Shah act as investment managers and disclaim beneficial ownership except to the extent of their pecuniary interests.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 51,258 shares ($1,268,594)
Net Buy
7 txns
Insider
RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
Role
null | null | null | null
Bought
51,258 shs ($1.27M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 14,149 | $24.47 | $346K |
| Purchase | Common Stock | 25,720 | $25.00 | $643K |
| Purchase | Common Stock | 1,483 | $24.98 | $37K |
| Purchase | Common Stock | 7,921 | $24.34 | $193K |
| Purchase | Common Stock | 1,985 | $24.95 | $50K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 6,340,063 shares (Indirect, See footnotes)
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.775 to $24.685 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II") and RA Capital Nexus IV Fund, L.P. (the "Nexus Fund IV"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Held directly by the Fund. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.84 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.80 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.93 to $24.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.93 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Held directly by Nexus Fund II. Held directly by Nexus Fund IV.
Key Figures
Shares purchased: 51,258 shares
Post-transaction holdings: 6,365,783 shares
Purchase price (May 11 block): $25.00 per share
+4 more
7 metrics
Shares purchased
51,258 shares
Total open-market buys over May 7–11
Post-transaction holdings
6,365,783 shares
Indirect Hemab common stock reported after latest purchase
Purchase price (May 11 block)
$25.00 per share
25,720-share open-market purchase
Purchase price (May 11 block)
$24.47 per share
14,149-share open-market purchase
Purchase price (May 8 block)
$24.98 per share
1,483-share open-market purchase
Purchase price (May 7 blocks)
$24.34–$24.95 per share
7,921- and 1,985-share open-market purchases
Number of buy transactions
5 transactions
Open-market purchases reported in Form 4
Key Terms
weighted average price, open-market purchase, beneficial ownership, pecuniary interest, +1 more
5 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market purchase financial
"transaction_action: "open-market purchase" for Common Stock transactions."
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
beneficial ownership financial
"disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaim beneficial ownership ... except to the extent of their pecuniary interest therein."
indirect ownership financial
"ownership_type: "indirect" and direct_or_indirect: "I" for the transactions."
FAQ
What insider activity did RA Capital report for Hemab Therapeutics (COAG)?
RA Capital–managed funds reported open-market purchases of Hemab Therapeutics Common Stock, totaling 51,258 shares over May 7–11. These transactions increased their indirect reported holdings to 6,365,783 shares, according to the Form 4 filing.
How many open-market purchase transactions did RA Capital report in Hemab (COAG)?
The summary data show five open-market purchase transactions in Hemab common stock, with a net effect of buying 51,258 shares. Two additional entries in the Form 4 reflect holdings rather than new buy or sell transactions.